As an immune checkpoint molecule, B7H3 is aberrantly expressed in 65% of SCLC tumors, where its overexpression drives disease progression and predicts poor survival, thereby nominating it as a promising immunotherapeutic target (59–61). The gene discussed is CD276; the disease is small cell lung carcinoma.